GlassScriptPhysician profile
Stacie Rose
NPI 1871194381
$2,697.25
in general payments reported to CMS, 2019-2025
16 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $175 · 2023: $1,279 · 2024: $864 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,397.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $410.94 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $407.16 | 2023-2024 | |
| Alkermes, INC. | $333.72 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $235.83 | 2021-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $217.06 | 2023-2025 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $199.64 | 2023-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $173.96 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $165.04 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Lundbeck LLC | $157.14 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $150.98 | 2022-2024 | Caplyta |
| Axsome Therapeutics, INC. | $89.99 | 2023-2025 | Auvelity |
| Corium, LLC | $53.43 | 2023-2024 | Azstarys |
| Idorsia Pharmaceuticals US INC | $32.18 | 2023 | Quviviq |
| Orexo US, INC. | $24.96 | 2022 | |
| Merck Sharp & Dohme LLC | $22.78 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $22.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacie Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.